drugset
Drugs / NVSI-06-09
last change Aug 2023 re-read 3 minutes ago

NVSI-06-09

Vaccine

Developed for
COVID-19
Investigated by
Beijing Institute of Biological Products Co Ltd. · China National Biotec Group Company Limited · Lanzhou Institute of Biological Products Co., Ltd · National Vaccine and Serum Institute, China

Trials 1

today NCT05293548 · Ph 2
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05293548 May 2022 → May 2023 COVID-19 National Vaccine and Serum Institute, China Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NVSI-06-09 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05293548 ↗
Modality Vaccine “Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)” NCT05293548 ↗
Route Intramuscular “Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09) in the deltoid muscle of the upper arm” NCT05293548 ↗